Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average rating of “Moderate Buy” by the seventeen brokerages that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $59.13.

Several research analysts have recently commented on the company. Chardan Capital decreased their target price on Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research report on Thursday. Citigroup reduced their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday. JPMorgan Chase & Co. reduced their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. The Goldman Sachs Group dropped their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Robert W. Baird dropped their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $15.95 on Tuesday. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -2.91 and a beta of 1.76. The business’s 50-day simple moving average is $20.71 and its 200 day simple moving average is $22.73. Intellia Therapeutics has a one year low of $15.35 and a one year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.40) earnings per share. On average, equities research analysts predict that Intellia Therapeutics will post -5.22 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the business. First Horizon Advisors Inc. raised its holdings in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares in the last quarter. Elmwood Wealth Management Inc. grew its position in Intellia Therapeutics by 0.9% during the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock worth $1,393,000 after acquiring an additional 600 shares during the last quarter. Interchange Capital Partners LLC grew its position in Intellia Therapeutics by 6.5% during the 1st quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company’s stock worth $303,000 after acquiring an additional 670 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after acquiring an additional 750 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.